⌕
Biocryst Pharmaceuticals · BCRX · Nasdaq
Tenet 73 · Solid
Compare
$7.45−2.10%At closeTenet 73 · Solid
$7.45−0.16 (−2.10%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Biocryst Pharmaceuticals (BCRX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 13, 2026 · 07:00 ETCOMPANY'S OWN WORDS
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting

— Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy —…

● Zacks Investment ResearchNov 10, 2026 · 10:16 ET
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth

TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.…

● Defense WorldNov 5, 2026 · 01:44 ET
Head-To-Head Review: BioCryst Pharmaceuticals (NASDAQ:BCRX) & Zenas BioPharma (NASDAQ:ZBIO)

BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on th…

● Seeking AlphaNov 4, 2026 · 15:34 ET
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Nick Wilder - Manager of Investor Relations Charles Gayer - CEO, President & Director Babar Ghias - CFO & He…

● Seeking AlphaNov 4, 2026 · 14:20 ET
BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst

BioCryst Pharmaceuticals delivered Q3 2026 results ahead of expectations, maintaining 2026 guidance and highlighting Orladeyo's ongoing growth in a competitive HAE market. BCRX's valuation appears modest at ~3.5x forward…

● MarketBeatNov 4, 2026 · 11:15 ET
BioCryst Pharmaceuticals Q3 Earnings Call Highlights

BioCryst Pharmaceuticals NASDAQ: BCRX reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while maintaining its full…

● Zacks Investment ResearchNov 4, 2026 · 09:56 ET
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.06 per share a year ago.…

● GlobeNewsWireNov 4, 2026 · 07:00 ETCOMPANY'S OWN WORDS
BioCryst Reports Third Quarter 2026 Financial Results

— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guida…

● Zacks Investment ResearchOct 30, 2026 · 10:55 ET
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

The consensus price target hints at a 137.9% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could me…

● Zacks Investment ResearchOct 28, 2026 · 11:06 ET
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● GlobeNewsWireOct 21, 2026 · 16:01 ETCOMPANY'S OWN WORDS
BioCryst to Report Third Quarter 2026 Financial Results on November 4

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November 4…

● GlobeNewsWireOct 21, 2026 · 07:00 ETCOMPANY'S OWN WORDS
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients' individual needs and preferences—…

● Defense WorldOct 21, 2026 · 04:15 ET
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Syndax Pharmaceuticals (NASDAQ:SNDX)

BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) and Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses b…

● GlobeNewsWireOct 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

—Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today anno…

● Defense WorldOct 2, 2026 · 06:15 ET
BioCryst Pharmaceuticals (NASDAQ:BCRX) and BioXcel Therapeutics (NASDAQ:BTAI) Financial Contrast

BioXcel Therapeutics (NASDAQ: BTAI - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies …

● Schaeffers ResearchSep 21, 2026 · 14:44 ET
Biopharma Stock With Layers of Technical Support in Place

After its most recent pullback, biopharmaceutical stock BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) bounced off the $8 level and has now reclaimed the 320-day moving average -- both of which have been key lines of pressur…

● MarketBeatSep 18, 2026 · 22:02 ET
BioCryst Eyes $1B Rare-Disease Future Through External Innovation

BioCryst Pharmaceuticals NASDAQ: BCRX is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charli…

● Zacks Investment ResearchSep 18, 2026 · 13:35 ET
4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.…

● Seeking AlphaSep 15, 2026 · 12:02 ET
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Seeking AlphaSep 11, 2026 · 10:16 ET
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity

BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations declined from $465.7 …

● GlobeNewsWireSep 1, 2026 · 07:00 ETCOMPANY'S OWN WORDS
BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Confere…

● Defense WorldSep 1, 2026 · 04:03 ET
Canada Pension Plan Investment Board Buys Shares of 115,805 BioCryst Pharmaceuticals, Inc. $BCRX

Canada Pension Plan Investment Board bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) during a recent quarter, according to the company in its most recent 13F filing with the Securities an…

● Zacks Investment ResearchAug 31, 2026 · 10:41 ET
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?

Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.…

● Seeking AlphaAug 28, 2026 · 11:59 ET
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve

BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding;…

● GlobeNewsWireAug 25, 2026 · 07:01 ETCOMPANY'S OWN WORDS
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.